Curebase

Headquartered in San Francisco, Curebase primarily offers a digital e-clinical suite that supports clinical trials in conducting a range of tasks, including 1) patient-reported outcomes, 2) clinical outcome assessments, 3) electronic consent, sourcing, and scheduling of patients, and 4) interactive response technology. The platform is compliant with HIPAA GDPR, 21 C.F.R Part 11, and ICH/GCP.

As of May 2022, the company had over 300 in-house staff, including clinical research coordinators, to support clients. The company had done 83 studies as of June 2024 In terms of geographic reach, Curebase operates in the US, UK, Canada, and France.

Key customers and partnerships

As of June 2024, the company’s solution had collected 8.4 million points of data, facilitated the signing of 30,000 consent forms and overseen participation from 250,000 participants across 83 studies. Some of its customers were Gilead, Johnson & Johnson, Persephone Biosciences, Walgreens, Mitsubishi Tanabe Pharma, and the Mayo Clinic. In terms of geographic reach, Curebase operates in the US, the UK, Canada, and France, with plans to expand into six more countries.

Funding and financials

The company raised USD 40 million in Series B funding in May 2022 led by Gilead. The proceeds were to be used to strengthen the product team, fund expansion into six new European countries, and develop the language support for these countries.